



164b

PATENT
ATTORNEY DOCKET NO. CIT1510-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Cope et al.
Serial No.: 10/047,253
Filed: January 14, 2002
Title: REGULATION OF TARGET PROTEIN ACTIVITY THROUGH MODIFIER
PROTEINS

Art Unit: 1645
Examiner Unassigned

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 09 2002

TRANSMITTAL SHEET

TECH CENTER 1600:2900

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) An Information Disclosure Statement (2 pages);
- (2) A Form PTO-1449 (2 pages);
- (3) Eight (8) References;
- (4) International Search report (8 pages); and
- (5) Return postcard;

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, September 27, 2002 in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Jason Berry

Name of Person Mailing Paper

Signature

In the Application of

Cope et al.

Application Serial No.: 10/047,253

Filed: January 14, 2002

Page 2


PATENT

Attorney Docket No.: CIT1510-4

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated August 26, 2002, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: _____



Lisa A. Haile, Ph.D.

Registration No. 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP

4365 Executive Drive, Suite 1100

San Diego, California 92121-2133

United States Patent & Trademark Customer No. 28213

#7
9-6-03PATENT
ATTORNEY DOCKET NO. CIT1510-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Cope et al.
Serial No.: 10/047,253
Filed: January 14, 2002
Title: REGULATION OF TARGET PROTEIN ACTIVITY THROUGH MODIFIER
PROTEINSArt Unit: 1645
Examiner UnassignedCommissioner for Patents
Washington, D.C. 20231

RECEIVED

OCT 9 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, September 27, 2002 in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Jason Berry

Name of Person Mailing Paper

Signature


In the Application of
Cope et al.
Application Serial No.: 10/047,253
Filed: January 14, 2002

PATENT
Attorney Docket No.: CIT1510-4

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement as the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated August 26, 2002, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: 7/27/02




Lisa A. Haile, Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

United States Patent & Trademark Customer No. 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. CIT1510-4	Serial No.: 10/047,253
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicants: Cope et al. Filing Date: January 14, 2002	Group Art Unit: Unassigned



U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	6,165,731	12/26/2000	Deshaies et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

AB	Chamovitz and Segal, "JAB1/CSN5 and the COP9 Signosome: A Complex Situation," <i>EMBO Reports</i> , Vol. 2, No. 2, 2001, pgs. 96-101.
AC	Ciechanover, Aaron et al., "Ubiquitin-Mediated Proteolysis: Biological Regulation Via Destruction," <i>BioEssays</i> , Vol. 22, 2000, pgs. 442-451.
AD	Glickman, Michael H. et al., "The Regulatory Particle of the <i>Saccharomyces Cerevisiae</i> Proteasome," <i>Molecular and Cellular Biology</i> , Vol. 18, No. 6, June 1998, pgs. 3149-3162.
AE	Groll, Michael et al., "The Eukaryotic 20S Proteasome: A Potential Target for Drug Development," In DFG-Schwerpunkt, Struktur, Funktion und Regulation des 20S/26S Ubiquitin-Proteasomesystems Kolloquium, May 23-25, 2001, Program Abstract, accessed on Internet June 20, 2002 at www.dfg-sp-ubiquitin.de .
AF	Lyapina, Svetlana et al., "Promotion of NEDD8-CUL1 Conjugate Cleavage By COP9 Signosome," <i>Science</i> , Vol. 292, May 18, 2001, pgs. 1382-1385.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449


Gray Cary:GT\6314276.1
104662-94

RECEIVED

OCT 09 2002

TECH CENTER 1600/2900

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. CIT1510-4	Serial No.: 10/047,253
	Applicants: Cope et al.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: January 14, 2002	Group Art Unit: Unassigned



	AG	Meiners, Silke et al., "Role of the Ubiquitin-Protease Pathway In Vascular Restenosis – Proteasome Inhibition As A New Therapeutic Approach," In DFG-Schwerpunkt, Struktur, Funktion und Regulation des 20S/26S Ubiquitin-Proteasomesystems Kolloquium, May 23-25, 2001, Program Abstract, accessed on Internet June 20, 2002 at www.dfg-sp-ubiquitin.de.
	AH	Wei, Ning et al., "The COP9 Complex Is Conserved Between Plants and Mammals and Is Related to the 26S Proteasome Regulatory Complex," <i>Current Biology</i> , Vol. 8, No. 16, July 27, 1998, pgs. 919-922 and S1 and S2.

RECEIVED

OCT 09 2002

TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

Gray Cary\GT\6314276.1
104662-94